Special Issue

Impact of Pandemic of COVID-19 on Antibiotic Prescription/Sales and on Antibiotic Resistances

Message from the Guest Editor

COVID-19 can present as a severe respiratory infection, and is being or has been treated with a wide variety of antibiotics. Accordingly, there is profound concern globally about the impact that the COVID-19 pandemic may have on the overprescription of antibiotics, in view of the consequences which this could have for humans, animals, and the environment. Even so, there are few studies on this topic, and the main subjects of this Special Issue thus include:

- An assessment of the impact on the prescription/sale of antibiotics as a whole at a country and/or regional level;
- The effect on the amount of antibiotics prescribed, by reference to the health care setting (primary care/hospital care/emergencies/critical care); and,
- Trends in the prescribing of watch and/or reserve group antibiotics, according to the WHO criteria.

Of special interest in this respect are studies conducted across extensive geographical areas such as regions or countries, which, on the basis of a number of papers, would enable an idea to be formed of the impact on the prescription/sale of antibiotics worldwide.

Guest Editor

Prof. Dr. Adolfo Figueiras

- 1. Department of Preventive Medicine, University of Santiago de Compostela, R/ San Francisco, s/n, 15782 Santiago, Spain
- 2. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBER-ESP), Madrid, Spain
- 3. Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain

Deadline for manuscript submissions

closed (31 December 2021)



an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



mdpi.com/si/75200

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

